Genprex (GNPX) Prices 7.62M Share Common Offering at $1.05/Sh

Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new and potentially life-saving approach to treating some of the world’s most deadly cancers based upon a novel proprietary technology platform, today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 7,620,000 shares of common stock, par value $0.001 per share at an offering price of $1.05 per share, pursuant to a registered direct offering, priced at-the-market under Nasdaq rules. There are no warrants in the offering. The gross proceeds of the offering will be approximately $8,000,000 before deducting fees and other estimated offering expenses. The Company intends to use the net proceeds to advance its lead clinical programs in non-small cell lung cancer (NSCLC) and for working capital and general corporate purposes. The closing of the registered direct offering is expected to take place on or about January 27, 2020, subject to the satisfaction of customary closing conditions.

A.G.P./Alliance Global Partners is acting as lead placement agent for the offering.

Joseph Gunnar & Co., LLC is acting as co-placement agent for the offering.

You May Also Be Interested In

• Elutia secures $26M in financing to advance NXT-41x to market
• DeFi Technologies posts $7.8M revenue and $2.3M loss in Q2 2026
• Alpha Cognition reports Q2 2026 revenue of $6M as net loss narrows